The Coagulation Factor VIII pipeline drugs market research report outlays comprehensive information on the Coagulation Factor VIII targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Coagulation Factor VIII pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
Smarter leaders trust GlobalData
The report also covers products from therapy areas such as Hematological Disorders which include the indications Hemophilia A (Factor VIII Deficiency), and Von Willebrand Disease (vWD). It also reviews key players involved in Coagulation Factor VIII targeted therapeutics development with respective active and dormant or discontinued products.
The Coagulation Factor VIII pipeline targets constitutes close to 58 molecules. Out of which, approximately 53 molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I, IND/ CTA Filed, Preclinical, and Discovery stages are 2, 10, 7, 4, 1, 18, and 10 respectively. Similarly, the universities portfolio in Preclinical, and Discovery comprises 4, and 1 molecule.
Coagulation Factor VIII overview
Coagulation factor VIII (FVIII) is a large protein that plays a critical role in blood clotting. It is also known as antihemophilic factor A since its deficiency causes hemophilia A, the most common inherited bleeding disorder. In normal individuals, FVIII circulates in the bloodstream in an inactive form bound to another protein called von Willebrand factor (vWF). When an injury occurs and blood vessels are damaged, FVIII is activated and released from vWF. The activated form of FVIII, FVIIIa, interacts with another coagulation factor, factor IXa, to form a complex that converts factor X to factor Xa. Factor Xa then goes on to activate prothrombin to thrombin, the enzyme responsible for fibrin clot formation.
For a complete picture of Coagulation Factor VIII’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.
Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
